The Churn of Power How Political Upheaval Could Reshape Market Dynamics Estate Planning Questions Handling CDs for a Parent in Hospice Care CPF LIFE as a Retirement Anchor How Stable Payouts Could Support Your Expenses Teslas Latest Software Update Targets Competitive Pressures in China Market GMs AllElectric Cadillac Vistiq A New Luxury EV With 300Mile Range SpaceX OpenAI and Anthropic May Surpass Berkshire Hathaways Market Value on Debut Polymarket Suggests McKesson MCK Q1 2026 Earnings EPS Slightly Beats Estimates Stock Holds Steady OTLY Q1 2026 Earnings Losses Narrow Sharply as Cost Improvements Exceed Expectations LUMN Q1 2026 Earnings EPS Misses Estimates by Wide Margin as Restructuring Challenges Persist ESAB Q1 2026 Earnings EPS Miss Amid Market Challenges VSCO Q1 2026 Earnings Earnings Beat Estimates Despite Limited Revenue Disclosure Cass Information Systems Inc Q1 2026 Earnings Solid EPS Beat Amid Mixed Market Response Journey Medical DERM Holds Steady at 596 as Stock Consolidates Between Key Levels Playboy Inc PLBY Moves Higher Amid Renewed Interest Testing Key Resistance Viking Holdings VIK Holds Steady Near Support as Investors Weigh Fundamentals OFS Capital Corporation 495 Notes due 2028 OFSSH Hold Steady at 239 as Market Awaits Direction Andretti Acquisition Corp II POLE Holds Steady at 1071 as SPAC Investors Eye Potential Business Combination DSGR Q1 2026 Earnings EPS Surpasses Estimates Stock Reacts Positively POWL Q1 2026 Earnings EPS Misses Estimates Amidst Operational Headwinds MT Bank MTB Q1 2026 Earnings EPS Beat Amidst Stable Loan Activity Creative Realities Inc Q1 2026 Earnings Significant EPS Miss Amidst Operational Challenges ITT Q1 2026 Earnings Strong EPS Beat Amid Mixed Market Reaction WGRX Q1 2026 Earnings Negative EPS and No Revenue Reported Stock Plunges 22 International Aid Sector Faces Structural Pressures as Overhead Costs Under Scrutiny Analysis Suggests NLY Q1 2026 Earnings Slight EPS Beat Amid Uncertain Rate Environment and Modest Stock Decline Precision BioSciences DTIL Jumps 484 as Biotech Sentiment Improves